Zhang Qi, Chen Yun-Er, Zhu Xin-Xin, Wang Xia, Qu Ai-Juan
Department of Physiology and Pathophysiology, School of Basic Medical Sciences, Capital Medical University, Beijing 100069, China.
Center for Infectious Diseases, Beijing Youan Hospital, Capital Medical University, Beijing 100069, China.
Sheng Li Xue Bao. 2023 Jun 25;75(3):390-402.
Heart failure with preserved ejection fraction (HFpEF) is a type of heart failure characterized by left ventricular diastolic dysfunction with preserved ejection fraction. With the aging of the population and the increasing prevalence of metabolic diseases, such as hypertension, obesity and diabetes, the prevalence of HFpEF is increasing. Compared with heart failure with reduced ejection fraction (HFrEF), conventional anti-heart failure drugs failed to reduce the mortality in HFpEF due to the complex pathophysiological mechanism and multiple comorbidities of HFpEF. It is known that the main changes of cardiac structure of in HFpEF are cardiac hypertrophy, myocardial fibrosis and left ventricular hypertrophy, and HFpEF is commonly associated with obesity, diabetes, hypertension, renal dysfunction and other diseases, but how these comorbidities cause structural and functional damage to the heart is not completely clear. Recent studies have shown that immune inflammatory response plays a vital role in the progression of HFpEF. This review focuses on the latest research progress in the role of inflammation in the process of HFpEF and the potential application of anti-inflammatory therapy in HFpEF, hoping to provide new research ideas and theoretical basis for the clinical prevention and treatment in HFpEF.
射血分数保留的心力衰竭（HFpEF）是一种以左心室舒张功能障碍伴射血分数保留为特征的心力衰竭类型。随着人口老龄化以及代谢性疾病（如高血压、肥胖和糖尿病）患病率的不断上升，HFpEF的患病率也在增加。与射血分数降低的心力衰竭（HFrEF）相比，由于HFpEF复杂的病理生理机制和多种合并症，传统的抗心力衰竭药物未能降低HFpEF的死亡率。已知HFpEF心脏结构的主要变化是心肌肥厚、心肌纤维化和左心室肥厚，并且HFpEF通常与肥胖、糖尿病、高血压、肾功能不全等疾病相关，但这些合并症如何导致心脏结构和功能损害尚不完全清楚。最近的研究表明，免疫炎症反应在HFpEF的进展中起着至关重要的作用。本综述重点关注炎症在HFpEF过程中的作用以及抗炎治疗在HFpEF中的潜在应用的最新研究进展，希望为HFpEF的临床防治提供新的研究思路和理论依据。
